ProfileGDS5678 / 1454683_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 62% 57% 54% 62% 60% 66% 49% 42% 52% 53% 56% 60% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2747851
GSM967853U87-EV human glioblastoma xenograft - Control 23.727862
GSM967854U87-EV human glioblastoma xenograft - Control 33.4437357
GSM967855U87-EV human glioblastoma xenograft - Control 43.2871454
GSM967856U87-EV human glioblastoma xenograft - Control 53.6484562
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6909560
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0068766
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1691449
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9407342
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2484352
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2934453
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3892756
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5924260
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4507357